Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

omestic) and 1-617-213-8852 (international) prior to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, June 26, 2008, at 12:30 PM ET and will be accessible until Thursday, July 3, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 27175887.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through July 26, 2008.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia for which Vanda submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2007. The FDA accepted Vanda's iloperidone NDA for filing in November 2007 and Vanda expects a decision from the FDA on or about July 27, 2008. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Cautionary Note Regarding Forward-Looking Sta
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Lockton Dunning Benefits, the Dallas ... of Vice President Kim Foerster on ... team, Excelsior Solutions. Foerster brings ... position.  Most recently, she worked as the Director ... where she has held various managerial positions since ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... UV disinfection robot, announced today that the General Services ... through November 2019.   This newly formed ... all levels of government purchasers, including Department of Veteran ... as Homeland Security contacts purchasing solutions for the Ebola ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 2011 /PRNewswire-iReach/ --  Janet R. Dees, CEO/President of ... opening of its newest vascular access center in Columbus, ... success for American Vascular Access, LLC., and the addition ... R. Dees, CEO/President.   "Our goal has continued ...
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... of its CLS® Brevius ™ Hip Stem with ... new technology enables surgeons to better match patients, individual ... adjustments. "Following its introduction in Europe earlier ...
Cached Medicine Technology:American Vascular Access Continues Growth in Georgia 2Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States 2Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States 3
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry ... affordable quality regarding heating, cooling and plumbing services in ... by the “Queen of Clean” for impressive contractor services ... reputation over the years for providing outstanding quality customer ... contractor services for both homeowners and businesses. Linda Cobb, ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... Susan Lark, MD, noted medical researcher and women,s health practitioner, has ... Reclast, as well as other oral bisphosphonates such as Boniva, Actonel, ... ... 2008 -- Susan Lark, MD , noted medical researcher and ...
... doctors urge everyone to kick the habit , , THURSDAY, ... Month in November, female smokers should take advantage of ... steps toward kicking the habit, urges The American College ... smoking takes an average of 14.5 years off women,s ...
... study finds , , THURSDAY, Nov. 27 (HealthDay News) -- ... sugar-sweetened drinks from school cafeteria menus will have little ... Because these drinks are believed to be a ... the United States, many schools across the nation are ...
... 27 The Committee for Human,Medicinal Products ... approval,for once-daily dosing of 800 mg PREZISTA(R) ... therapy in treatment-naive adults (those who,have never ... inhibitor, was,developed by Tibotec Pharmaceuticals, and Tibotec, ...
... /PRNewswire-Asia-FirstCall/ -- China,s leading,integrated medical device and healthcare ... "the Company", Stock Code: 8180.HK) is,pleased to announce ... Investment Management Limited ("Atlantis Investment") as financial,investors through ... at a price,HK$1.03 per share. , ...
... to benefit healthcare services for seasonal vineyard workers and their families. ... preview outstanding 2007 vintage. , ... Portland, OR (PRWEB) ... Noir Auction contributed generously to the 17th annual benefit with animated ...
Cached Medicine News:Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Women Smokers Lose 14.5 Years Off Life Span 2Health News:School Soda Ban Has Limited Effect 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 4Health News:Golden Meditech Brings in Financial Investor Through New Share Issuance 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 3
... Siemens introduces the AXIOM Artis ... first biplane magnetic navigation system equipped ... both planes, which is uniquely capable ... of catheter-based procedures to facilitate increased ...
... AXIOM Artis dTC is a versatile ... the cardiology department from preparation to ... interventional procedures. With AXIOM Artis dTC, your ... the cardiology department that leaves you free ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... AXIOM Artis BC is a ... system architecture ideal for cardiological ... and ergonomic architecture enables you ... configuration to focus on:, ...
Medicine Products: